Form 8-K - Current report:
SEC Accession No. 0001683168-25-002193
Filing Date
2025-04-02
Accepted
2025-04-02 10:50:45
Documents
16
Period of Report
2025-04-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT sunshine_8k.htm   iXBRL 8-K 29076
2 PRESS RELEASE sunshine_ex9901.htm EX-99.1 14509
3 GRAPHIC image_010.jpg GRAPHIC 8135
  Complete submission text file 0001683168-25-002193.txt   282224

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE sbfm-20250401.xsd EX-101.SCH 3553
5 XBRL DEFINITION FILE sbfm-20250401_def.xml EX-101.DEF 29992
6 XBRL LABEL FILE sbfm-20250401_lab.xml EX-101.LAB 36550
7 XBRL PRESENTATION FILE sbfm-20250401_pre.xml EX-101.PRE 27015
18 EXTRACTED XBRL INSTANCE DOCUMENT sunshine_8k_htm.xml XML 5521
Mailing Address 333 LAS OLAS WAY CU4 SUITE 433 FORT LAUDERDALE FL 33301
Business Address 333 LAS OLAS WAY CU4 SUITE 433 FORT LAUDERDALE FL 33301 954-515-0810
Sunshine Biopharma Inc. (Filer) CIK: 0001402328 (see all company filings)

EIN.: 205566275 | State of Incorp.: CO | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41282 | Film No.: 25802662
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)